[go: up one dir, main page]

HK40117787A - Stable formulations of shr0302 - Google Patents

Stable formulations of shr0302 Download PDF

Info

Publication number
HK40117787A
HK40117787A HK62025105842.1A HK62025105842A HK40117787A HK 40117787 A HK40117787 A HK 40117787A HK 62025105842 A HK62025105842 A HK 62025105842A HK 40117787 A HK40117787 A HK 40117787A
Authority
HK
Hong Kong
Prior art keywords
shr0302
stable formulations
formulations
stable
Prior art date
Application number
HK62025105842.1A
Other languages
Chinese (zh)
Inventor
Herbert R. Brinkman
Jason Michael Carbol
Original Assignee
Arcutis Biotherapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arcutis Biotherapeutics, Inc. filed Critical Arcutis Biotherapeutics, Inc.
Publication of HK40117787A publication Critical patent/HK40117787A/en

Links

HK62025105842.1A 2021-12-15 2022-12-14 Stable formulations of shr0302 HK40117787A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63/289,780 2021-12-15
US63/370,740 2022-08-08

Publications (1)

Publication Number Publication Date
HK40117787A true HK40117787A (en) 2025-05-23

Family

ID=

Similar Documents

Publication Publication Date Title
EP4251153A4 (en) Lyophilized formulations of tegavivint
EP4099999A4 (en) Formulations of docetaxel
EP4057941A4 (en) Stable formulations of silk-derived protein
HK40117787A (en) Stable formulations of shr0302
HK40112689A (en) Formulations of radiprodil
HK40105577A (en) Stable ruc-4 formulations
IL313482A (en) Stable formulations of shr0302
HK40115248A (en) Formulations of docetaxel
HK40116379A (en) Formulations of docetaxel
HK40116380A (en) Formulations of docetaxel
HK40115571A (en) Formulations of docetaxel
HK40115247A (en) Formulations of docetaxel
HK40101567A (en) Oral formulations of tenapanor
HK40087872A (en) Formulations of cabazitaxel
HK40106938A (en) Formulations of l-asparaginase
AU2022903170A0 (en) Stable API Formulations
HK40117580A (en) Combination formulation of cedazuridine
HK40122546A (en) Combination formulation of cedazuridine
HK40100081A (en) Lipid formulations of triazoloquinazolinone compounds
HK40102138A (en) Formulations of psilocybin
HK40109219A (en) Formulations of apremilast
HK40090532A (en) Formulations of anti-il-33 antibodies
HK40085045A (en) Topical formulations of (1s)-1-phenyl-2-pyridin-2-ylethanamine
HK40109650A (en) Formulations
HK40109619A (en) Formulations